Ensign Group (ENSG) has drawn investor attention after a period of strong share price moves, with the stock up about 25% over the past month and roughly 17% in the past 3 months.
See our latest analysis for Ensign Group.
Those short term share price moves sit within a wider pattern, with a year to date share price return of 23.14% and a 1 year total shareholder return of 66.10%, suggesting momentum has been building rather than fading.
If strong recent gains in healthcare operators have your attention, it could be a good moment to broaden your watchlist with our screener: 28 healthcare AI stocks.
With Ensign Group now trading near its recent highs and with only a small gap to the average analyst price target, the key question is simple: is there still a buying opportunity here, or has the market already priced in future growth?
Price to Earnings of 35.9x: Is it justified?
On simple earnings terms, Ensign Group looks expensive, with a P/E of 35.9x compared with a peer average of 18x and a US Healthcare average of 23.7x.
The P/E ratio compares the current share price with the company’s earnings per share and is a quick way to see how much investors are paying for each dollar of profit. For Ensign Group, a 35.9x multiple indicates the market is paying a much higher price for its earnings than for many other healthcare operators.
That premium sits well above both the peer group and the estimated fair P/E of 29.1x. This suggests the market is pricing in a stronger earnings profile than the regression based level the P/E could move toward over time.
Compared with the broader US Healthcare industry on 23.7x, Ensign Group’s 35.9x P/E stands out as distinctly higher. This points to investors assigning the company a rich earnings multiple relative to sector norms.
Explore the SWS fair ratio for Ensign Group
Result: Price-to-Earnings of 35.9x (OVERVALUED)
However, you still need to weigh risks, such as any slowdown in Ensign Group’s $5,057.841m revenue or pressure on its $343.971m net income, against that rich P/E.
Find out about the key risks to this Ensign Group narrative.
Another view: DCF points to a different story
The P/E math already paints Ensign Group as expensive, but our DCF model goes further, with an estimated future cash flow value of $148.89 versus the current $214.17 share price. On this view, the stock screens as overvalued, which raises a different question: is the market paying too much for quality?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ensign Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If the mixed signals on valuation have you on the fence, now is a good time to look through the numbers yourself and decide what they mean for you. To see what the market is optimistic about, take a look at 2 key rewards.
Looking for more investment ideas?
If this valuation check has sharpened your focus, do not stop here. Widen your net and see what else stands out on the screener.
- Chase value by reviewing companies that currently look attractively priced with our 49 high quality undervalued stocks curated from fundamental data.
- Prioritise resilience and capital protection by scanning 76 resilient stocks with low risk scores so you can focus on businesses with lower assessed risk profiles.
- Hunt for lesser known opportunities before the crowd by checking our screener containing 24 high quality undiscovered gems built to spotlight stocks that may still fly under most radars.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com